Sleep disturbances: number of participants with insomnia · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 0.25 mg changes sleep disturbances: number of participants with insomnia compared with placebo (very low certainty).
1 finding from 1 review
Depression · chronic pruritus of unknown origin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction · chronic pruritus of unknown origin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 5 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life · chronic pruritus of unknown origin
1 finding from 1 review
Sleep disturbances: number of participants with insomnia · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 5 mg changes sleep disturbances: number of participants with insomnia compared with placebo (very low certainty).
1 finding from 1 review
Depression · chronic pruritus of unknown origin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction · chronic pruritus of unknown origin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pruritus · chronic pruritus of unknown origin
Serlopitant 1 mg showed no clear difference in patient‐reported pruritus intensity compared with placebo (low certainty).
1 finding from 1 review
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 1 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life · chronic pruritus of unknown origin
1 finding from 1 review
Intervention not reported
Placebo · patients with moderate to severe eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Tezepelumab (1 RCT; 56 participants) · patients with moderate to severe eczema
The intervention showed no clear difference in tezepelumab (1 RCT; 56 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Lebrikizumab (1 RCT; 156 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes lebrikizumab (1 RCT; 156 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
PF‐04965842 (1 RCT; 211 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes PF‐04965842 (1 RCT; 211 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Tralokinumab (1 RCT; 153 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes tralokinumab (1 RCT; 153 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Apremilast (1 RCT; 121 participants) · patients with moderate to severe eczema
The intervention showed no clear difference in apremilast (1 RCT; 121 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Baricitinib (1 RCT; 75 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes baricitinib (1 RCT; 75 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Placebo · patients with moderate to severe eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Total studies: 6 RCTsTotal participants: 1720 · patients with moderate to severe eczema
1 finding from 1 review